Keywords: allogeneic cell cancer immunotherapy; autoimmune diseases; disease-modifying therapy; extracellular vesicle-based therapies; gene-engineered T cells; induced pluripotent stem cells (iPSCs)-derived cell therapy; virus-specific cytotoxic T lymphocytes.